119 related articles for article (PubMed ID: 29964149)
1. PTEN is indispensable for cells to respond to MAPK inhibitors in myeloid leukemia.
Zhang J; Xiang Z; Malaviarachchi PA; Yan Y; Baltz NJ; Emanuel PD; Liu YL
Cell Signal; 2018 Oct; 50():72-79. PubMed ID: 29964149
[TBL] [Abstract][Full Text] [Related]
2. Shp2E76K mutant confers cytokine-independent survival of TF-1 myeloid cells by up-regulating Bcl-XL.
Ren Y; Chen Z; Chen L; Woods NT; Reuther GW; Cheng JQ; Wang HG; Wu J
J Biol Chem; 2007 Dec; 282(50):36463-73. PubMed ID: 17942397
[TBL] [Abstract][Full Text] [Related]
3. Cytokine-specific activation of distinct mitogen-activated protein kinase subtype cascades in human neutrophils stimulated by granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, and tumor necrosis factor-alpha.
Suzuki K; Hino M; Hato F; Tatsumi N; Kitagawa S
Blood; 1999 Jan; 93(1):341-9. PubMed ID: 9864179
[TBL] [Abstract][Full Text] [Related]
4. Tyrosine phosphorylation of proteins in primary human myeloid leukemia cells stimulated by cytokines: analysis of the frequency of phosphorylation, and partial identification and semi-quantification of signaling molecules.
Hagiwara S; Iki S; Urabe A; Saeki K; Miwa A; Togawa A; Ozawa K; Takaku F; Yuo A
Int J Hematol; 1998 Dec; 68(4):387-401. PubMed ID: 9885438
[TBL] [Abstract][Full Text] [Related]
5. Mcl-1 is a common target of stem cell factor and interleukin-5 for apoptosis prevention activity via MEK/MAPK and PI-3K/Akt pathways.
Huang HM; Huang CJ; Yen JJ
Blood; 2000 Sep; 96(5):1764-71. PubMed ID: 10961875
[TBL] [Abstract][Full Text] [Related]
6. Deregulation of tumor suppressive ASXL1-PTEN/AKT axis in myeloid malignancies.
Cao L; Xia X; Kong Y; Jia F; Yuan B; Li R; Li Q; Wang Y; Cui M; Dai Z; Zheng H; Christensen J; Zhou Y; Wu X
J Mol Cell Biol; 2020 Sep; 12(9):688-699. PubMed ID: 32236560
[TBL] [Abstract][Full Text] [Related]
7. TGFbeta inhibits GM-CSF-induced phosphorylation of ERK and MEK in human myeloid leukaemia cell lines via inhibition of phosphatidylinositol 3-kinase (PI3-k).
Montenegro DE; Franklin T; Moscinski LC; Zuckerman KS; Hu XT
Cell Prolif; 2009 Feb; 42(1):1-9. PubMed ID: 19143758
[TBL] [Abstract][Full Text] [Related]
8. Prolonged activation of the mitogen-activated protein kinase pathway is required for macrophage-like differentiation of a human myeloid leukemic cell line.
Hu X; Moscinski LC; Valkov NI; Fisher AB; Hill BJ; Zuckerman KS
Cell Growth Differ; 2000 Apr; 11(4):191-200. PubMed ID: 10775036
[TBL] [Abstract][Full Text] [Related]
9. Timing of the loss of Pten protein determines disease severity in a mouse model of myeloid malignancy.
Liu YL; Yan Y; Webster C; Shao L; Lensing SY; Ni H; Feng W; Colorado N; Pathak R; Xiang Z; Hauer-Jensen M; Li S; Zhou D; Emanuel PD
Blood; 2016 Apr; 127(15):1912-22. PubMed ID: 26764354
[TBL] [Abstract][Full Text] [Related]
10. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
11. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
Wu Z; Gioeli D; Conaway M; Weber MJ; Theodorescu D
Prostate; 2008 Jun; 68(9):935-44. PubMed ID: 18386291
[TBL] [Abstract][Full Text] [Related]
12. Src inhibitors, PP2 and dasatinib, increase retinoic acid-induced association of Lyn and c-Raf (S259) and enhance MAPK-dependent differentiation of myeloid leukemia cells.
Congleton J; MacDonald R; Yen A
Leukemia; 2012 Jun; 26(6):1180-8. PubMed ID: 22182854
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte-macrophage colony-stimulating factor (GM-CSF) induces antiapoptotic and proapoptotic signals in acute myeloid leukemia.
Faderl S; Harris D; Van Q; Kantarjian HM; Talpaz M; Estrov Z
Blood; 2003 Jul; 102(2):630-7. PubMed ID: 12663443
[TBL] [Abstract][Full Text] [Related]
14. PTEN's regulation of VEGF and VEGFR1 expression and its clinical significance in myeloid leukemia.
Zhiyong C; Wentong L; Xiaoyang Y; Ling P
Med Oncol; 2012 Jun; 29(2):1084-92. PubMed ID: 21360018
[TBL] [Abstract][Full Text] [Related]
15. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
[TBL] [Abstract][Full Text] [Related]
16. Expression of the protein phosphatase 1 inhibitor KEPI is downregulated in breast cancer cell lines and tissues and involved in the regulation of the tumor suppressor EGR1 via the MEK-ERK pathway.
Wenzel K; Daskalow K; Herse F; Seitz S; Zacharias U; Schenk JA; Schulz H; Hubner N; Micheel B; Schlag PM; Osterziel KJ; Ozcelik C; Scherneck S; Jandrig B
Biol Chem; 2007 May; 388(5):489-95. PubMed ID: 17516844
[TBL] [Abstract][Full Text] [Related]
17. Interferon-gamma enhances human eosinophil effector functions induced by granulocyte-macrophage colony-stimulating factor or interleukin-5.
Yamaguchi T; Kimura H; Kurabayashi M; Kozawa K; Kato M
Immunol Lett; 2008 Jun; 118(1):88-95. PubMed ID: 18440651
[TBL] [Abstract][Full Text] [Related]
18. Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase.
Fu X; Creighton CJ; Biswal NC; Kumar V; Shea M; Herrera S; Contreras A; Gutierrez C; Wang T; Nanda S; Giuliano M; Morrison G; Nardone A; Karlin KL; Westbrook TF; Heiser LM; Anur P; Spellman P; Guichard SM; Smith PD; Davies BR; Klinowska T; Lee AV; Mills GB; Rimawi MF; Hilsenbeck SG; Gray JW; Joshi A; Osborne CK; Schiff R
Breast Cancer Res; 2014 Sep; 16(5):430. PubMed ID: 25212826
[TBL] [Abstract][Full Text] [Related]
19. PTEN regulation by Akt-EGR1-ARF-PTEN axis.
Yu J; Zhang SS; Saito K; Williams S; Arimura Y; Ma Y; Ke Y; Baron V; Mercola D; Feng GS; Adamson E; Mustelin T
EMBO J; 2009 Jan; 28(1):21-33. PubMed ID: 19057511
[TBL] [Abstract][Full Text] [Related]
20. Long-term exposure of leukemia cells to multi-targeted tyrosine kinase inhibitor induces activations of AKT, ERK and STAT5 signaling via epigenetic silencing of the PTEN gene.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
Leukemia; 2010 Sep; 24(9):1631-40. PubMed ID: 20596030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
